Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
After finishing at $4.48 in the prior trading day, Cardiff Oncology Inc (NASDAQ: CRDF) closed at $3.52, down -21.43%. In other words, the price has decreased by -$21.43 from its previous closing price. On the day, 2.14 million shares were traded. CRDF stock price reached its highest trading level at $4.42 during the session, while it also had its lowest trading level at $3.12.
Ratios:
Our goal is to gain a better understanding of CRDF by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.91 and its Current Ratio is at 5.91. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.02.
On December 08, 2021, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $19.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 19 ’23 when PACE GARY W bought 30,000 shares for $1.37 per share. The transaction valued at 41,100 led to the insider holds 697,761 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRDF now has a Market Capitalization of 157380608 and an Enterprise Value of 127479720. For the stock, the TTM Price-to-Sale (P/S) ratio is 258.06 while its Price-to-Book (P/B) ratio in mrq is 2.58. Its current Enterprise Value per Revenue stands at 261.229 whereas that against EBITDA is -2.832.
Stock Price History:
The Beta on a monthly basis for CRDF is 1.97, which has changed by 1.488889 over the last 52 weeks, in comparison to a change of 0.22379243 over the same period for the S&P500. Over the past 52 weeks, CRDF has reached a high of $6.42, while it has fallen to a 52-week low of $0.94. The 50-Day Moving Average of the stock is -21.00%, while the 200-Day Moving Average is calculated to be 57.58%.
Shares Statistics:
The stock has traded on average 1.92M shares per day over the past 3-months and 617440 shares per day over the last 10 days, according to various share statistics. A total of 44.68M shares are outstanding, with a floating share count of 41.11M. Insiders hold about 8.07% of the company’s shares, while institutions hold 12.77% stake in the company. Shares short for CRDF as of 1713139200 were 3987551 with a Short Ratio of 2.08, compared to 1710460800 on 2813413. Therefore, it implies a Short% of Shares Outstanding of 3987551 and a Short% of Float of 9.19.
Earnings Estimates
The stock of Cardiff Oncology Inc (CRDF) is currently being evaluated by 4.0 analysts who are actively contributing to its market rating.On average, analysts expect EPS of -$0.25 for the current quarter, with a high estimate of -$0.24 and a low estimate of -$0.26, while EPS last year was -$0.25. The consensus estimate for the next quarter is -$0.26, with high estimates of -$0.24 and low estimates of -$0.28.
Analysts are recommending an EPS of between -$0.85 and -$1.04 for the fiscal current year, implying an average EPS of -$0.98. EPS for the following year is -$1.06, with 3.0 analysts recommending between -$0.8 and -$1.19.
Revenue Estimates
A total of 4 analysts have provided revenue estimates for CRDF’s current fiscal year. The highest revenue estimate was $770k, while the lowest revenue estimate was $210k, resulting in an average revenue estimate of $400k. In the same quarter a year ago, actual revenue was $488k
